Amyloid-targeting Alzheimer’s drugs ‘probably’ not effective Authors of a Cochrane review said that any effect that donanemab and lecanemab have on cognitive function and dementia severity at 18 months was “trivial”.…
NICE opens consultation on previously-rejected Alzheimer’s treatments donanemab and lecanemab The consultation follows an appeal by the manufacturers of donanemab and lecanemab after NICE said it would not recommend the drugs for NHS use for a third time.…
Health news round-up: antidepressants, hospital admissions and rheumatology workforce A weekly summary of important developments in pharmacy and health news that you may have missed.…
Health news round-up: Alzheimer’s treatment, retatrutide results and kidney cancer guidelines A weekly summary of important developments in pharmacy and health news that you may have missed.…
Antipsychotic prescribing in dementia does not follow NICE guidance, study shows Researchers found that the prescribing of antipsychotics for older people with dementia goes on longer than advised, which increases the risk of avoidable harms.…
Health news round up: long-term conditions, cancer drugs and a medicines pricing stand-off Senior clinical reporter Joanna Robertson summarises some important developments in health news.…
Health news round-up: NICE approvals, fighting AMR and medicines safety concerns Senior clinical reporter Joanna Robertson summarises some important developments in health news.…
Diagnosis and management of dementia A detailed overview of dementia and how pharmacists can provide long-term support for individuals and families.…
NICE rejects Alzheimer’s disease drugs for third time The National Institute for Health and Clinical Excellence said the benefits of donanemab and lecanemab in the treatment of Alzheimer's disease are too small to justify their high costs to the NHS.…
Alzheimer’s treatments donanemab and lecanemab still not recommended under latest NICE draft guidance NICE says that the cost of implementing donanemab and lecanemab across the NHS is “significantly higher” than considered acceptable for taxpayers’ money and NHS resources.…
